BorgJJAislaitnerGPirozynskiMMifsudS. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to?Drug Saf. 2011;34:187-197.
2.
ClarkRHBloomBTSpitzerARGerstmannDR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117:1979-1987.
3.
CuzzolinLAtzeiAFanosV. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5:703-718.
4.
HorenBMontastrucJLLapeyre-MestreM. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665-670.
5.
EgualeTBuckeridgeDLVermaA. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 2015;2:1-9.
MasonJPirmohamedMNunnT. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol. 2012;68:21-28.
